関連ニュース

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript

Mirum Pharmaceuticals is approaching major catalysts, notably the FDA's PDUFA decision for zilurgisertib (Sept. 26) & pivotal Phase 3 data on its chronic hepatitis D drug, a potential blockbuster. MIR

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript